Clinical characteristics of participants
. | Wild type . | Prothrombin 20210A . |
|---|---|---|
| No. (%) | 228 (49) | 236* (51) |
| Men, % | 46 | 46 |
| Mean age at inclusion, y (range) | 46 (15-87) | 45 (15-91) |
| Mean follow-up duration, mo (range) | 46 (7-84) | 48 (7-84) |
| Previous VTE, % | 7.9† | 13.6† |
| Previous arterial cardiovascular events, % | 5.7‡ | 5.5‡ |
| Smoking, % | 31.1 | 33.1 |
| Hypertension, % | 28.1 | 26.3 |
| Dyslipidemia, % | 18.9 | 12.7 |
| Diabetes mellitus, % | 6.1 | 3.0 |
. | Wild type . | Prothrombin 20210A . |
|---|---|---|
| No. (%) | 228 (49) | 236* (51) |
| Men, % | 46 | 46 |
| Mean age at inclusion, y (range) | 46 (15-87) | 45 (15-91) |
| Mean follow-up duration, mo (range) | 46 (7-84) | 48 (7-84) |
| Previous VTE, % | 7.9† | 13.6† |
| Previous arterial cardiovascular events, % | 5.7‡ | 5.5‡ |
| Smoking, % | 31.1 | 33.1 |
| Hypertension, % | 28.1 | 26.3 |
| Dyslipidemia, % | 18.9 | 12.7 |
| Diabetes mellitus, % | 6.1 | 3.0 |